drugset / Trial / NCT02989493

Testing Doxazosin to Treat Stress Mechanisms in Alcoholism

NCT02989493

RandomizedParallel-groupTriple-blindTreatment

Summary

Double-blind, placebo controlled, randomized controlled trial (RCT) for Alcohol Use Disorder examining the effects of doxazosin, a norepinephrine alpha1 receptor antagonist, on stress reactivity and clinical outcomes.

Timeline

Start
2017-04-12
Primary completion
2020-03-13
Completion
2020-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxazosin Small molecule 8 mg

Indications